Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ

Virnig, 2010, Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes, JNCI J Natl Cancer Inst, 102, 170, 10.1093/jnci/djp482

Independent, 2012, Panel on breast cancer screening. The benefits and harms of breast cancer screening: an independent review, Lancet, 380, 1778, 10.1016/S0140-6736(12)61611-0

Narod, 2015, Breast cancer mortality after a diagnosis of ductal carcinoma in situ, JAMA Oncol, 1, 888, 10.1001/jamaoncol.2015.2510

Sagara, 2015, Survival benefit of breast surgery for low-grade ductal carcinoma in situ, JAMA Surg, 150, 739, 10.1001/jamasurg.2015.0876

Benson, 2016, Treatment of low-risk ductal carcinoma in situ: is nothing better than something?, Lancet Oncol, 17, e442, 10.1016/S1470-2045(16)30367-9

Meyerson, 2011, Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ, Breast, 20, 529, 10.1016/j.breast.2011.06.001

Ryser, 2016, Outcomes of active surveillance for ductal carcinoma in situ: a computational risk analysis, JNCI J Natl Cancer Inst, 108, 10.1093/jnci/djv372

Francis, 2015, Addressing overtreatment of screen detected DCIS; the LORIS trial, Eur J Cancer, 51, 2296, 10.1016/j.ejca.2015.07.017

Patient-Centered Outcomes Research Institute

Elshof, 2015, Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study, Eur J Cancer, 51, 1497, 10.1016/j.ejca.2015.05.008

Erbas, 2006, The natural history of ductal carcinoma in situ of the breast: a review, Breast Cancer Res Treat, 97, 135, 10.1007/s10549-005-9101-z

Welch, 1997, Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find?, Ann Intern Med, 127, 1023, 10.7326/0003-4819-127-11-199712010-00014

Worni, 2014, Trends in treatment patterns and outcomes for DCIS patients: a SEER population-based analysis, J Clin Oncol, 32, 1007, 10.1200/jco.2014.32.15_suppl.1007

Ozanne, 2011, Characterizing the impact of 25 years of DCIS treatment, Breast Cancer Res Treat, 129, 165, 10.1007/s10549-011-1430-5

Wallis, 2012, The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS, Br J Cancer, 106, 1611, 10.1038/bjc.2012.151

Vicini, 2013, Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy, Breast J, 19, 365, 10.1111/tbj.12127

Kong, 2014, Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis, Curr Oncol, 21, e96, 10.3747/co.21.1604

Cronin, 2016, Impact of age on risk of recurrence of ductal carcinoma in situ: outcomes of 2996 women treated with breast-conserving surgery over 30 years, Ann Surg Oncol, 23, 2816, 10.1245/s10434-016-5249-5

Holmberg, 2013, Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study, Br J Cancer, 108, 812, 10.1038/bjc.2013.26

Thurfjell, 2001, Mammographic finding as predictor of survival in 1-9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone, Breast Cancer Res Treat, 67, 177, 10.1023/A:1010648919150

Tabar, 2004, Mammographic tumor features can predict long-term outcomes reliably in women with 1-14-mm invasive breast carcinoma, Cancer, 101, 1745, 10.1002/cncr.20582

Peacock, 2004, Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator?, Clin Radiol, 59, 165, 10.1016/j.crad.2003.07.006

James, 2003, Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?, Clin Radiol, 58, 54, 10.1053/crad.2002.1110

Evans, 2004, Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: is this a reliable prognostic indicator?, Clin Radiol, 59, 163, 10.1016/j.crad.2003.07.007

Brennan, 2011, Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer, Radiology, 260, 119, 10.1148/radiol.11102368

Jakub, 2017, A validated nomogram to predict upstaging of ductal carcinoma in situ to invasive disease, Ann Surg Oncol, 24, 2915, 10.1245/s10434-017-5927-y

Cuzick, 2011, Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial, Lancet Oncol, 12, 21, 10.1016/S1470-2045(10)70266-7

Fisher, 1999, Tamoxifen in treatment of intraductal breast cancer: national Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial, Lancet, 353, 1993, 10.1016/S0140-6736(99)05036-9

Forbes, 2016, Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in post-menopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial, Lancet, 387, 866, 10.1016/S0140-6736(15)01129-0

Margolese, 2016, Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial, Lancet, 387, 849, 10.1016/S0140-6736(15)01168-X

Maxwell, 2001, A study of breast cancers detected in the incident round of the UK NHS breast screening programme: the importance of early detection and treatment of ductal carcinoma in situ, Breast, 10, 392, 10.1054/brst.1999.0266

Duffy, 2016, Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study, Lancet Oncol, 17, 109, 10.1016/S1470-2045(15)00446-5

Elston, 2000, Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast, Eur J Cancer, 36, 1769, 10.1016/S0959-8049(00)00181-7

Ellis, 2006, Impact of a national external quality assessment scheme for breast pathology in the UK, J Clin Pathol, 59, 138, 10.1136/jcp.2004.025551

Ernster, 1996, Incidence of and treatment for ductal carcinoma in situ of the breast, JAMA, 275, 913, 10.1001/jama.1996.03530360023033

Barnes, 2014, The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast, Eur J Surg Oncol, 40, 249, 10.1016/j.ejso.2013.12.013

Roulson, 2005, Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review, Histopathology, 47, 551, 10.1111/j.1365-2559.2005.02243.x

Møller, 2011, Completeness of case ascertainment and survival time error in English cancer registries: impact on 1-year survival estimates, Br J Cancer, 105, 170, 10.1038/bjc.2011.168

Solin, 1996, Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast, J Clin Oncol, 14, 754, 10.1200/JCO.1996.14.3.754

Early Breast Cancer Trialists' Collaborative Group EBCTCG, 2010, Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast, J Natl Cancer Inst Monogr, 2010, 162, 10.1093/jncimonographs/lgq039

Doebar, 2016, Ductal carcinoma in situ diagnosed by breast needle biopsy: predictors of invasion in the excision specimen, Breast, 27, 15, 10.1016/j.breast.2016.02.014

Caswell-Smith, 2017, Ductal carcinoma in situ: is core needle biopsy ever enough?, J Med Imaging Radiat Oncol, 61, 29, 10.1111/1754-9485.12503